FAIRMOUNT FUNDS MANAGEMENT LLC
Q2 2022 Form 13-F
WEST CONSHOHOCKEN, PENNSYLVANIA
CIK 0001802528
· CRD 284844
· SEC-registered investment adviser
$436.9M Reported Value Total
FAIRMOUNT FUNDS MANAGEMENT LLC reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $862,548,839, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $6.1B gross asset value
Hedge Fund: $5.7B · Private Equity Fund: $342.0M
Source: Form ADV filed 2026-08-07
Reported value
$436.9M
Quarter over quarter
-15.1%
Holdings
27
Top-10 concentration
66.9%
Key People
Form ADV owners & control persons
Peter Evan Harwin
MANAGING MEMBER
Tomas Kiselak
MANAGING MEMBER
Emily Florence Curtiss
GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 15, 2022 |
| Form | 13F-HR |
| Reported value | $436.9M |
| Positions | 27 |
| Change in reported value | +3.3% |
| New positions | 6 |
| Exited positions | 1 |
| Position turnover | 25.0% |
| Top-10 concentration | 66.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
12 | $1.6B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
12 | $1.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
17 | $771.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
15 | $644.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
17 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $885.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
15 | $917.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
16 | $946.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
20 | $831.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $709.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
16 | $581.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
16 | $630.4M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
26 | $568.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
27 | $436.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
22 | $422.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
20 | $303.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BHVN BIOHAVEN PHARMACTL HLDG CO | $38.5M | 8.81% |
| 2 | AXSM AXSOME THERAPEUTICS INC | $36.1M | 8.26% |
| 3 | BCRX BIOCRYST PHARMACEUTICALS INC | $35.4M | 8.1% |
| 4 | GBT GLOBAL BLOOD THERAPEUTICS IN | $30.5M | 6.97% |
| 5 | ARGX ARGENX SE | $27.9M | 6.38% |
| 6 | NBIX NEUROCRINE BIOSCIENCES INC | $27.6M | 6.31% |
| 7 | INSM INSMED INC | $26.2M | 5.99% |
| 8 | COGT COGENT BIOSCIENCES INC | $24.9M | 5.7% |
| 9 | NUVL NUVALENT INC | $23.3M | 5.32% |
| 10 | ENTA ENANTA PHARMACEUTICALS INC | $22.2M | 5.08% |
| 11 | ONC BEIGENE LTD | $18.0M | 4.13% |
| 12 | CTIC CTI BIOPHARMA CORP | $13.4M | 3.07% |
| 13 | PNT POINT BIOPHARMA GLOBAL INC | $12.5M | 2.86% |
| 14 | DBVT DBV TECHNOLOGIES SA | $12.3M | 2.82% |
| 15 | VRDN VIRIDIAN THERAPEUTICS INC | $10.9M | 2.5% |
| 16 | ANNX ANNEXON INC | $10.9M | 2.5% |
| 17 | OLMA OLEMA PHARMACEUTICALS INC | $10.9M | 2.49% |
| 18 | ACAD ACADIA PHARMACEUTICALS INC | $10.6M | 2.42% |
| 19 | TYRA TYRA BIOSCIENCES INC | $10.1M | 2.32% |
| 20 | AMRN AMARIN CORP PLC | $8.3M | 1.9% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.